Palisade Bio provided updates on its Phase 2 clinical programs, including its ulcerative colitis study and a separate Crohn's disease trial. The company reported continued enrollment progress and outlined expected timelines for upcoming clinical data. 🔹 Key Highlights Phase 2 Ulcerative Colitis: The study is enrolling 204 patients across once-daily 15 mg and 30 mg doses, compared with placebo. Topline Timeline: Results are expected in Q4 2027. Site Activation: 29 of 30 planned U.S. sites have been activated, with approximately 115 sites planned globally. Phase 2 Crohn's Disease: A separate 60-patient open-label study is progressing toward site activation before the end of 2026. Crohn's Data: Topline results are expected in Q1 2028. Potential Earlier Update: The company may provide an earlier update after a meaningful patient cohort completes 12 weeks of treatment, depending on enrollment progress. 💡 Why It Matters Progress across both ulcerative colitis and Crohn's disease programs could expand Palisade Bio's opportunities in inflammatory bowel disease. Site activation and enrollment execution will be important near-term milestones. However, the programs remain clinical-stage, and the investment outlook depends on safety, efficacy, and future trial results. Source: X — @dough 🚀 Start Your 7-Day FREE ThinkSabio Trial https://www.thinksabio.com/ ThinkSabio — Stocks Simplified